Statins for all: The new premed?

British Journal of Anaesthesia

Volumn 103, Issue 1, 2009, Pages 99-107

  Brookes, Z L S ^a   McGown, C C ^a   Reilly, C S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Complications, sepsis; Heart, ischaemia; Inhibitors, reductase, hydroxymethylglutaryl CoA; Nitric oxide; Nitric oxide synthase; Pharmacology, statins

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NCX 6550; NCX 6560; NITRIC OXIDE; NITROATORVASTATIN; NITROPRAVASTATIN; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; EVIDENCE BASED PRACTICE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; STROKE; ANIMAL; METHODOLOGY; MOUSE; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PREMEDICATION; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; PERIOPERATIVE CARE; PREMEDICATION; SEPSIS;

EID: 67650716526     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep149     Document Type: Review

References (81)

1. Aboyans V, Labrousse L, Lacroix P, et al. Predictive factors of stroke in patients undergoing coronary bypass grafting: statins are protective. Eur J Cardiothorac Surg 2006; 30: 300-4
2. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-5
3. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109: 7-15
4. Alvarez de Sotomayor M, Vega S, Mingorance C, Marhuenda E, Herrera MD. Effects of HMG-CoA reductase inhibition by sim-vastatin on vascular dysfunction induced by lipopolysaccharide in rats. Pharmacology 2008; 82: 89-96
5. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38: 3198-204
6. Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture; results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164: 146-52
7. Durant R, Klouche K, Delbosc S, et al. Superoxide anion overproduction in sepsis: effects of vitamin E and simvastatin. Shock 2004; 22: 34-9
8. Durazzo AES, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39: 967-76
9. Fauchier L, Bertrand P, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation. J Am Coll Cardiol 2008; 51: 828-35
10. Fleisher LE, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Circulation 2007; 116: e418-500
11. Földes G, von Haehling S, Okonko DO, Jankowska EA, Poole-Wilson PA, Anker SD. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol 2008; 240: 80-5
12. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601
13. Gao F, Linhartova L, Johnston AM, Thickett DR. Statins and sepsis. Br J Anaesth 2008; 100: 288-98
14. Gardiner SM, Kemp PA, March JE, Bennett T. Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats. Br J Pharmacol 1995; 116: 2005-16
15. Garrean S, Gao XP, Brovkovych V, et al. Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol 2006; 177: 4853-60
16. Giusti-Paiva A, Martinez MR, Felix JV, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 2004; 21: 271-5
17. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70: 2364-70
18. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367: 413-8
19. Hamilton SJ, Chew GT, Watts GF. Coenzyme q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 2009; 32: 810-2
20. Handa O, Stephen J, Cepinskas G. Role of endothelial nitric oxide synthase-derived nitric oxide in activation and dysfunction of cerebrovascular endothelial cells during early onsets of sepsis. Am J Physiol Heart Circ Physiol 2008; 295: H1712-9
21. Hayashi T, Matsui-Hirai H, Fukatsu A, et al. Selective iNOS inhibitor, ONO1714 successfully retards the development of high-cholesterol diet induced atherosclerosis by novel mechanism. Atherosclerosis 2006; 187: 316-24
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
23. Heart Protection Study Collaborative Group. Lifetime cost effectiveness of simvastatin in a range of risk groups derived from a randomised trial of 20536 people. Br Med J 2006; 333: 1145-9
24. Heo SK, Yun HJ, Noh EK, Park WH, Park SD. LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. Immunol Lett 2008; 120: 57-64
25. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006; 105: 1260-72
26. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43: 642-8
27. Jantzen F, Konemann S, Wolff B, et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J Physiol Pharmacol 2007; 58: 503-14
28. Javanmard SH, Nematbakhsh M, Mahmoodi F, Mohajeri MR. L-Arginine supplementation enhances eNOS expression in experimental model of hypercholesterolemic rabbits aorta. Pathophysiology 2009; 16: 9-13
29. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2002; 356: 1627-31
30. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005; 5: 141-54
31. Kadoi Y, Goto F. Effects of selective iNOS inhibition on systemic hemodynamics and mortality rate on endotoxic shock in streptozotocin-induced diabetic rats. Shock 2007; 28: 602-9
32. Kao CC, Bandi V, Guntupalli KK, Wu M, Castillo L, Jahoor F. Arginine, citrulline, and nitric oxide metabolism in sepsis. Clin Sci (Lond) 2008 (Epub ahead of print, December 23)
33. Klein R, Klein BE, Tomany SC, Danforth LG, Cruickshanks KJ. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003; 121: 1151-5
34. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006; 32: 75-9
35. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942: 23-30
36. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-71
37. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007; 104: 1326-33
38. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30
39. Madonna R, De Caterina R. Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb Haemost 2009; 101: 345-50
40. Madonna R, Di Napoli P, Massaro M, et al. Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 2005; 280: 13503-11
41. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13
42. Matsuda N, Hayashi Y, Takahashi Y, Hattori Y. Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: reversal effect of fluvastatin therapy. J Pharmacol Exp Ther 2006; 319: 1348-54
43. McGown CC, Brookes ZLS. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth 2007; 98: 163-75
44. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40: 1609-14
45. Menasché P. The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Curr Opin Cardiol 1995; 10: 597-604
46. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005; 112: 117-24
47. Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109: 2560-5
48. Momi S, Impagnatiello F, Guzzetta M, et al. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol 2007; 570: 115-24
49. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42
50. Nachtigal P, Kopecky M, Solichova D, Zdansky P, Semecky V. The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J Pharm Pharmacol 2005; 57: 197-203
51. Niessner A, Steiner S, Speidl WS, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006; 189: 408-13
52. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2004; 291: 1071-80
53. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-43
54. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424
55. Palinski W, Tsimikas S. Immunolomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002; 13: 1673-81
56. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2006; 114: 1455-61
57. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in Scandinavian simvastatin survival study. Arch Intern Med 1996; 156: 2085-92
58. Poldermans D, Schouten O, Bax J, Winkel TA. Reducing cardiac risk in non-cardiac surgery: evidence from the DECREASE studies. Eur Heart J 2009; 11: A9-14
59. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207
60. Rossiello MR, Momi S, Caracchini R, et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrom-botic activity and inhibits tissue factor expression. J Thromb Haemost 2005; 3: 2554-62
61. Sabroe I, Parker LC, Dower SK, Whyte MK. The role of TLR activation in inflammation. J Pathol 2008; 214: 126-35
62. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet 1994; 344: 1182-6
63. Sade K, Schwartz D, Wolman Y, et al. Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glomeruli. J Lab Clin Med 1999; 134: 471-7
64. Sasaki M, Bharwani S, Jordan P, et al. The 3-hydroxy-3- methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 2003; 305: 78-85
65. Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008; 19: 553-7
66. Schouten O, Hoeks SE, Welten GMJM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007; 100: 316-20
67. Scott JA, Mehta S, Duggan M, Bihari A, McCormack DG. Functional inhibition of constitutive nitric oxide synthase in a rat model of sepsis. Am J Respir Crit Care Med 2002; 165: 1426-32
68. Settergren M, Böhm F Rydén L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008; 29: 1753-60
69. Shiomi M, Yamada S, Amano Y, Nishimoto T, Ito T Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/ lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Br J Pharmacol 2008; 154: 949-57
70. Simons M, Schwarzler F Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-50
71. Sotiroudis TG, Kyrtopoulos SA. Anticarcinogenic compounds of olive oil and related biomarkers. Eur J Nutr 2008; 47: 69-72
72. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009; 32: 541-6
73. Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. Endothelium 2007; 14: 239-43
74. Tyml K, Li F Wilson JX. Septic impairment of capillary blood flow requires nicotinamide adenine dinucleotide phosphate oxidase but not nitric oxide synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide synthase-dependent mechanism. Crit Care Med 2008; 36: 2355-62
75. Upmacis RK, Crabtree MJ, Deeb RS, et al. Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol 2007; 293: H2878-87
76. Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003; 18: 265-72
77. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (≥12 months) follow-up intravascular ultrasound. Circulation 2003; 108:2757-62
78. Wagner AH, Schwabe O, Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 2002; 136: 143-9
79. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 21: 1440-5
80. Xie XQ, Shinozawa Y, Sasaki J. The effects of arginine and selective inducible nitric oxide synthase inhibitor on pathophysiology of sepsis in a CLP model. J Surg Res 2008; 146: 298-303
81. Zhou Z, Gengaro P, Wang W et al. Role of NF-kappaB and PI 3-kinase/Akt in TNF-alpha-induced cytotoxicity in microvascular endothelial cells. Am J Physiol Renal Physiol 2008; 295: 932-41